Literature DB >> 22684274

[Cervical cancer screening in Germany. Current status].

V Schneider1.   

Abstract

Cervical cancer screening was introduced in Germany 40 years ago and the incidence of cancer of the cervix has subsequently decreased by close to 70%. The remaining incidence of 5,600 cases per year represents only 2.8% of all newly occurring cases of cancer in women and these cases occur mainly in patients who do not participate in regular screening. Thus, cervical cancer screening by cytological smears has been proven to be successful. The structure of the German cancer screening program is characterized by decentralized organization, exclusive involvement of medical specialists such as gynecologists and pathologists and strict quality assurance. The recruitment is 50% on a yearly basis and the cumulative participation over 3 years reaches 79%. Since 2008 all laboratories are required to report complete data sets to local quality control agencies.The Joint Federal Committee in charge of evaluating new technologies in Germany mandated an inquiry into the possible role of screening by human papillomavirus (HPV) testing. According to this report published by the Institute for Quality Assurance and Efficiency in Healthcare there are indications for advantages. There are, however, no data in the literature as to possible disadvantages of HPV testing. A similar study for the US Preventive Services Task Force was published in May 2011 with almost identical conclusions.

Entities:  

Mesh:

Year:  2012        PMID: 22684274     DOI: 10.1007/s00292-012-1579-7

Source DB:  PubMed          Journal:  Pathologe        ISSN: 0172-8113            Impact factor:   1.011


  12 in total

1.  [HPV-induced diseases of the female genital tract].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2011-11       Impact factor: 1.011

2.  The German cervical cancer screening model: development and validation of a decision-analytic model for cervical cancer screening in Germany.

Authors:  Uwe Siebert; Gaby Sroczynski; Peter Hillemanns; Jutta Engel; Roland Stabenow; Christa Stegmaier; Kerstin Voigt; Bernhard Gibis; Dieter Hölzel; Sue J Goldie
Journal:  Eur J Public Health       Date:  2006-02-09       Impact factor: 3.367

3.  Cervical cancer screening policies and coverage in Europe.

Authors:  Ahti Anttila; Lawrence von Karsa; Auni Aasmaa; Muriel Fender; Julietta Patnick; Matejka Rebolj; Florian Nicula; Laszlo Vass; Zdravka Valerianova; Lydia Voti; Catherine Sauvaget; Guglielmo Ronco
Journal:  Eur J Cancer       Date:  2009-08-19       Impact factor: 9.162

4.  Description of the national situation of cervical cancer screening in the member states of the European Union.

Authors:  Ahti Anttila; Guglielmo Ronco
Journal:  Eur J Cancer       Date:  2009-09-08       Impact factor: 9.162

5.  Routine audit of large-scale cervical cancer screening programs.

Authors:  Jack Cuzick
Journal:  J Natl Cancer Inst       Date:  2008-04-29       Impact factor: 13.506

Review 6.  Screening for the prevention of cervical cancer in the era of human papillomavirus vaccination: an Australian perspective.

Authors:  Annabelle Farnsworth
Journal:  Acta Cytol       Date:  2011-07-22       Impact factor: 2.319

7.  International incidence rates of invasive cervical cancer before cytological screening.

Authors:  L Gustafsson; J Pontén; R Bergström; H O Adami
Journal:  Int J Cancer       Date:  1997-04-10       Impact factor: 7.396

8.  Persistent carcinoma in cervical cancer screening: non-participation is the most significant cause.

Authors:  Katrin Marquardt; Heinz H Büttner; Ulf Broschewitz; Malte Barten; Volker Schneider
Journal:  Acta Cytol       Date:  2011-10-08       Impact factor: 2.319

9.  Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice.

Authors:  Y Yan; I J Dunkel; X Guan; D H Abramson; S C Jhanwar; R J O'Reilly
Journal:  Eur J Cancer       Date:  2000-01       Impact factor: 9.162

Review 10.  How to evaluate emerging technologies in cervical cancer screening?

Authors:  Marc Arbyn; Guglielmo Ronco; Jack Cuzick; Nicolas Wentzensen; Philip E Castle
Journal:  Int J Cancer       Date:  2009-12-01       Impact factor: 7.396

View more
  2 in total

1.  [Where is gynecological cytology in Germany going from here?].

Authors:  D Schmidt
Journal:  Pathologe       Date:  2012-11       Impact factor: 1.011

2.  Cytology use for cervical cancer screening in Portugal: results from the 2005/2006 National Health Survey.

Authors:  Mariana Oliveira; Bárbara Peleteiro; Nuno Lunet
Journal:  Eur J Public Health       Date:  2013-06-20       Impact factor: 3.367

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.